Strategic Financial Services, Inc, Novo Cure LTD Transaction History

Strategic Financial Services, Inc,

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $126,625 - $212,059	-1,090 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$130.4 - $225.58 $352,080 - $609,066	-2,700 Reduced 71.24%	1,090 $242,000
Q2 2020 Aug 11, 2020	SELL	$57.2 - $74.41 $71,500 - $93,012	-1,250 Reduced 24.8%	3,790 $225,000
Q1 2020 May 08, 2020	BUY	$57.05 - $95.75 $73,594 - $123,517	1,290 Added 34.4%	5,040 $339,000
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $34,023 - $53,790	-550 Reduced 12.79%	3,750 $280,000
Q1 2019 Apr 23, 2019	BUY	$31.96 - $56.12 $137,428 - $241,316	4,300 New	4,300 $207,000
Q4 2018 Feb 11, 2019	SELL	$28.72 - $52.63 $143,600 - $263,150	-5,000 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$32.0 - $52.4 $160,000 - $262,000	5,000 New	5,000 $262,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.07B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Strategic Financial Services, Inc,, based on Form 13F filings with the SEC.

Stay updated on Strategic Financial Services, Inc, with notifications on news.